Organovo Holdings (ONVO) Shares are Down -0.26%

Organovo Holdings (ONVO) : During the past 4 weeks, traders have been relatively bearish on Organovo Holdings (ONVO), hence the stock is down -14.83% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.76% relative to the S&P 500. The 4-week change in the price of the stock is -14.95% and the stock has fallen -0.26% in the past 1 week.

The stock has recorded a 20-day Moving Average of 8.35% and the 50-Day Moving Average is 4.5%.The 200 Day SMA reached 33.12%. Organovo Holdings, Inc. is up 31.19% in the last 3-month period. Year-to-Date the stock performance stands at 55.42%.


Organovo Holdings (NYSEMKT:ONVO): After opening at $3.79, the stock dipped to an intraday low of $3.75 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $3.91 and the buying power remained strong till the end. The stock closed at $3.87 for the day, a gain of 2.11% for the day session. The total traded volume was 420,874. The stocks close on the previous trading day was $3.79.

Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.